Get the Stockscreener App
367.89
0.40%
1.65
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $367.89, with a volume of 327.76K.
It is up +0.40% in the last 24 hours and up +6.67% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$366.24
Open:
$369.225
24h Volume:
327.76K
Relative Volume:
0.13
Market Cap:
$198.54B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.58
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.62%
1M Performance:
+6.67%
6M Performance:
+5.95%
1Y Performance:
+20.29%
1-Day Range:
$366.75
$371.00
1-Week Range:
$357.74
$378.54
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
367.86 | 196.55B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,166.93 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.85 | 598.96B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.03 | 447.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.11 | 307.25B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.66 | 285.37B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Settles Lawsuit for $74 Million Over Tax Disclosure Delay - GuruFocus
Working capital per share of Amgen Inc. – BCS:AMGN1 - TradingView
Amgen stock trades steadily as recent results and pipeline shape investor sentiment - Ad-hoc-news.de
PNC Financial Services Group Inc. Buys 24,577 Shares of Amgen Inc. $AMGN - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $12.14 Million in Amgen Inc. $AMGN - MarketBeat
ABN Amro Investment Solutions Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as Repatha growth offsets biosimilar pressure - Ad-hoc-news.de
Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced? - Yahoo! Finance Canada
Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong - simplywall.st
More Than Dry Eyes: The Many Faces of Sjögren’s Disease - Amgen
Amgen To Pay $74M To End Investor Suit Over $10.7B Tax Bill - Law360
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Benzinga
Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill - Fierce Pharma
Amgen Settles Investor Suit Over Tax Liability for $74 Million - Bloomberg Law News
Amgen stock trades steady as obesity pipeline and recent earnings shape outlook - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill - Reuters
Amgen stock holds near its yearly range as investors await the next earnings date. - Ad-hoc-news.de
Commerzbank Aktiengesellschaft FI Raises Position in Amgen Inc. $AMGN - MarketBeat
Andra AP fonden Has $17.72 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady on latest earnings context - Ad-hoc-news.de
Amgen stock trades steadily as oncology pipeline and recent earnings shape sentiment - Ad-hoc-news.de
Amgen stock trades steady as investors weigh recent revenue growth and obesity pipeline progress - Ad-hoc-news.de
Amgen stock trades steadily as cardiovascular drug data and oncology pipeline shape outlook - Ad-hoc-news.de
Amgen Earnings Preview: What to Expect - Barchart.com
Amgen stock edges higher as investors weigh latest revenue and pipeline metrics - Ad-hoc-news.de
KBC Group NV Sells 319,966 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Decker Wealth Management LLC Purchases New Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
AlTi Global Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
FY2026 EPS Estimates for Amgen Lowered by Erste Group Bank - MarketBeat
Amgen stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Amgen stock steadies as investors digest recent earnings and pipeline updates - ad-hoc-news.de
Amgen stock holds support as investors weigh earnings - ad-hoc-news.de
Valley Wealth Managers Inc. Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Mediolanum International Funds Ltd Buys 7,075 Shares of Amgen Inc. $AMGN - MarketBeat
Swiss National Bank Buys 105,080 Shares of Amgen Inc. $AMGN - MarketBeat
5,891 Shares in Amgen Inc. $AMGN Bought by Independent Financial Group LLC - MarketBeat
Amgen stock trades steady as investors digest Repatha growth and oncology pipeline - Ad-hoc-news.de
AIA Group Ltd Grows Stake in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) RBC Capital Markets Global Healthcare Conference 2025 Summary - Quartr
Amgen stock trades steady as oncology and obesity pipeline shapes investor focus - ad-hoc-news.de
Amgen stock trades steadily as oncology pipeline and recent revenue gains frame investor focus - ad-hoc-news.de
Amgen stock holds steady as earnings and guidance frame the outlook - ad-hoc-news.de
Amgen stock trades steady as recent earnings and drug pipeline shape outlook - ad-hoc-news.de
John G Ullman & Associates Inc. Sells 6,675 Shares of Amgen Inc. $AMGN - MarketBeat
Modera Wealth Management LLC Sells 4,769 Shares of Amgen Inc. $AMGN - MarketBeat
Illinois Municipal Retirement Fund Has $5.38 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Lowered by California Public Employees Retirement System - MarketBeat
Amgen Inc. $AMGN Holdings Decreased by Bartlett & CO. Wealth Management LLC - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):